Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Aveanna (AVAH) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Aveanna Healthcare (AVAH - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.02 per share, reflecting an increase of 33.3% compared to the same period last year. Revenues are forecasted to be $450.04 million, representing a year-over-year increase of 1.6%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Aveanna metrics that are commonly monitored and projected by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- PDS' will likely reach $361.29 million. The estimate indicates a change of +1.6% from the prior-year quarter.
Analysts expect 'Revenue- MS' to come in at $37.74 million. The estimate indicates a year-over-year change of +0.5%.
The consensus estimate for 'Revenue- HHH' stands at $51.22 million. The estimate suggests a change of +2.7% year over year.
View all Key Company Metrics for Aveanna here>>>
Aveanna shares have witnessed a change of +35.4% in the past month, in contrast to the Zacks S&P 500 composite's +1.7% move. With a Zacks Rank #1 (Strong Buy), AVAH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>